At a Glance
- Companies: Novartis and Orionis Biosciences
- Deal value: Up to $1.4 billion
- Focus area: Challenging therapeutic targets
- Deal type: Second collaboration between the companies
- Next steps: Advance discovery programmes under the alliance
What happened?
Novartis has entered into a second collaboration with Orionis Biosciences, with the new deal valued at up to $1.4 billion. The partnership is aimed at tackling therapeutic targets that are considered difficult to address with conventional drug discovery approaches.
Why does it matter?
Big pharma is increasingly turning to smaller biotech partners for access to specialised platforms that can reach hard-to-drug biology. A second deal suggests Novartis sees enough promise in Orionis’ approach to deepen the relationship and broaden its shot at discovering differentiated medicines.
Who’s behind it?
Novartis is a global pharmaceutical company with a broad focus across oncology, immunology, cardiovascular disease and neuroscience. Orionis Biosciences is a biotech company built around technologies designed to identify and pursue challenging protein targets.
How was it achieved?
The collaboration appears to build on an existing working relationship between the two companies, expanding their efforts into additional programmes or targets. The structure likely combines upfront payments with milestone-based value, a common way to spread risk while retaining upside for both sides.
What’s next?
The companies will now move programmes under the agreement through discovery and early development. If the collaboration performs well, it could produce additional candidates for Novartis’ pipeline and further validate Orionis’ platform.